In such cases, our aims were to summarize a much broader evidence base and to indirectly compare the relative efficacy and safety of these treatments with most comprehensive therapies (AZP, MTX, COT, COC, CYP, DPM, UDCA, MTX plus UDCA, COT plus UDCA, COC plus UDCA or BEF plus UDCA) for patients with PBC. This evidence concerns the gene PPIG and primary biliary cholangitis.